Comprehensive Analysis of Myoferlin in Human Pancreatic Cancer Via Bioinformatics

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Dec 27

PMID 34957301

Citations 1

Authors

Rou Pi

Yanmei Chen

Yijie Du

Suzhen Dong

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death and urgently needs biomarkers for clinical diagnosis and prognosis. It has been reported that myoferlin (MYOF) is implicated in the regulation of proliferation, invasion, and migration of tumor cells in many cancers including pancreatic cancer. To confirm the prognostic value of MYOF in pancreatic cancer, a comprehensive cancer versus healthy people analysis was conducted using public data. MYOF mRNA expression levels were compared in many kinds of cancers including pancreatic cancer via the Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) databases. The results have shown that MYOF mRNA expression levels were upregulated in most types of cancers, especially in pancreatic cancer, compared with healthy people's tissues. Data from the Cancer Cell Line Encyclopedia (CCLE) and European Bioinformatics Institute (EMBL-EML) database also revealed that MYOF mRNA is highly expressed in most cancer cells, particularly in pancreatic cancer cell lines. Furthermore, the prognostic value of MYOF was evaluated using GEPIA and Long-term Outcome and Gene Expression Profiling Database of pan-cancers (LOGpc) database. Higher expression of MYOF was associated with poorer overall survival, especially in the lower stage and lower grade. Coexpressed genes, possible regulators, and the correlation between MYOF expressions were analyzed via the GEPIA and LinkedOmics database. Nineteen coexpressed genes were identified, and most of these genes were related to cancer. The Tumor Immune Estimation Resource (TIMER) database was used to analyze the correlation between MYOF and immune response. Notably, we found that MYOF might have a potential novel immune regulatory role in tumor immunity. These results support that MYOF is a candidate prognostic biomarker for pancreatic cancer, which calls for further genomics research of pancreatic cancer and deeply functional studies on MYOF.

Citing Articles

Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration.

Shi H, Cheng Y, Shi Q, Liu W, Yang X, Wang S Front Oncol. 2022; 12:905230.

PMID: 36147922 PMC: 9486956. DOI: 10.3389/fonc.2022.905230.

References

Iacobuzio-Donahue C, Maitra A, Olsen M, Lowe A, Van Heek N, Rosty C . Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003; 162(4):1151-62. PMC: 1851213. DOI: 10.1016/S0002-9440(10)63911-9. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Turtoi A, Blomme A, Bellahcene A, Gilles C, Hennequiere V, Peixoto P . Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res. 2013; 73(17):5438-48. DOI: 10.1158/0008-5472.CAN-13-1142. View

Grutzmann R, Pilarsky C, Ammerpohl O, Luttges J, Bohme A, Sipos B . Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 2004; 6(5):611-22. PMC: 1531666. DOI: 10.1593/neo.04295. View

Zhang J, Park S, Artime M, Summy J, Shah A, Bomser J . AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest. 2007; 117(10):2962-73. PMC: 1978423. DOI: 10.1172/JCI30710. View

Lux A, Kahlert C, Grutzmann R, Pilarsky C . c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. Int J Mol Sci. 2019; 20(13). PMC: 6651266. DOI: 10.3390/ijms20133305. View

Neel N, Rossman K, Martin T, Hayes T, Yeh J, Der C . The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. Mol Cell Biol. 2012; 32(8):1374-86. PMC: 3318593. DOI: 10.1128/MCB.06291-11. View

Fahmy K, Gonzalez A, Arafa M, Peixoto P, Bellahcene A, Turtoi A . Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer. Int J Cancer. 2015; 138(3):652-63. DOI: 10.1002/ijc.29820. View

Dong Y, Kang H, Liu H, Wang J, Guo Q, Song C . Myoferlin, a Membrane Protein with Emerging Oncogenic Roles. Biomed Res Int. 2019; 2019:7365913. PMC: 6885792. DOI: 10.1155/2019/7365913. View

10.

Huang Y, Laval S, van Remoortere A, Baudier J, Benaud C, Anderson L . AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J. 2006; 21(3):732-42. DOI: 10.1096/fj.06-6628com. View

11.

Segara D, Biankin A, Kench J, Langusch C, Dawson A, Skalicky D . Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res. 2005; 11(9):3587-96. DOI: 10.1158/1078-0432.CCR-04-1813. View

12.

Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A . YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology. 2016; 151(3):526-39. PMC: 5007286. DOI: 10.1053/j.gastro.2016.05.006. View

13.

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

14.

Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S . The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res. 2015; 43(W1):W580-4. PMC: 4489272. DOI: 10.1093/nar/gkv279. View

15.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

17.

McKinney K, Lee Y, Choi H, Groseclose G, Iannitti D, Martinie J . Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J Proteomics. 2010; 74(1):79-88. DOI: 10.1016/j.jprot.2010.08.006. View

18.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

19.

Ohshima K, Hatakeyama K, Kanto K, Ide T, Watanabe Y, Moromizato S . Comparative proteomic analysis identifies exosomal Eps8 protein as a potential metastatic biomarker for pancreatic cancer. Oncol Rep. 2018; 41(2):1019-1034. DOI: 10.3892/or.2018.6869. View

20.

Murphy S, Zweyer M, Henry M, Meleady P, Mundegar R, Swandulla D . Proteomic analysis of the sarcolemma-enriched fraction from dystrophic mdx-4cv skeletal muscle. J Proteomics. 2018; 191:212-227. DOI: 10.1016/j.jprot.2018.01.015. View